Related Experiment Video
Updated: Mar 17, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation,
Simona Granata1, Alessandra Dalla Gassa1, Gloria Bellin1
1Renal Unit, Department of Medicine, University Hospital of Verona, Piazzale Stefani 1, 37126 Verona, Italy.
Abstract:
Chronic kidney disease (CKD) is an increasing and global health problem with a great economic burden for healthcare system. Therefore to slow down the progression of this condition is a main objective in nephrology. It has been extensively reported that microinflammation, immune system deregulation, and oxidative stress contribute to CKD progression. Additionally, dialysis worsens this clinical condition because of the contact of blood with bioincompatible dialytic devices. Numerous studies have shown the close link between immune system impairment and CKD but most have been performed using classical biomolecular strategies. These methodologies are limited in their ability to discover new elements and enable measuring the simultaneous influence of multiple factors. The "omics" techniques could overcome these gaps. For example, transcriptomics has revealed that mitochondria and inflammasome have a role in pathogenesis of CKD and are pivotal elements in the cellular alterations leading to systemic complications. We believe that a larger employment of this technique, together with other "omics" methodologies, could help clinicians to obtain new pathogenetic insights, novel diagnostic biomarkers, and therapeutic targets. Finally, transcriptomics could allow clinicians to personalize therapeutic strategies according to individual genetic background (nutrigenomic and pharmacogenomic). In this review, we analyzed the available transcriptomic studies involving CKD patients.
Insights
Transcriptomics reveals key roles for mitochondria and inflammasomes in chronic kidney disease (CKD) progression. This "omics" approach offers new insights into CKD pathogenesis, biomarkers, and personalized treatments.
Area of Science:
- Nephrology
- Genomics
- Molecular Biology
Background:
- Chronic kidney disease (CKD) is a growing global health issue with significant economic impact.
- Microinflammation, immune dysregulation, and oxidative stress are known contributors to CKD progression.
- Dialysis can exacerbate CKD due to blood-device interactions.
Purpose of the Study:
- To review transcriptomic studies in chronic kidney disease (CKD) patients.
- To explore the potential of "omics" techniques in understanding CKD.
- To identify novel pathogenetic insights, biomarkers, and therapeutic targets for CKD.
Main Methods:
- Analysis of existing transcriptomic studies in CKD patients.
- Application of "omics" methodologies to investigate CKD pathogenesis.
- Review of literature linking molecular pathways to CKD complications.
Main Results:
- Transcriptomics has identified roles for mitochondria and inflammasomes in CKD pathogenesis.
- These molecular pathways are implicated in cellular alterations leading to systemic complications.
- "Omics" techniques offer advantages over classical methods for discovering new factors and assessing multiple influences.
Conclusions:
- Transcriptomics and other "omics" methods can provide new pathogenetic insights into CKD.
- These techniques may lead to novel diagnostic biomarkers and therapeutic targets for CKD.
- Transcriptomics holds promise for personalizing CKD therapies based on individual genetic profiles (nutrigenomics, pharmacogenomics).
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease III: Interprofessional Care
